Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
EBV VIRAL CAPSID ANTIGEN IGM ANTIBODY |
|||||||||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2231 Geisinger Epic ID: 14932 | ||||||||
SPECIMEN COLLECTION |
|||||||||
Specimen type: |
Serum | ||||||||
Preferred collection container: |
|||||||||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
||||||||
Specimen required: |
0.5 mL serum; minimum 0.2 mL | ||||||||
SPECIMEN PROCESSING |
|||||||||
Specimen processing instructions: |
Allow to clot. Centrifuge and submit 0.5 mL serum. | ||||||||
Transport temperature: |
Refrigerated (preferred). Room temperature (stable 8 hours) or frozen specimen also acceptable. | ||||||||
Specimen stability: |
Room temperature: 8 hours. 2-8°C: 96 hours. Frozen: 6 months. | ||||||||
Rejection criteria: |
Stability exceeded or gross hemolysis. | ||||||||
TEST DETAILS |
|||||||||
Interpretation guide: |
NOTE: This test is for the qualitative determination of IgM antibodies to EBV VCA. |
||||||||
CPT code(s): |
86665 | ||||||||
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | |||||||||
Test includes: |
Antibody detection to EBVCA IgM. | ||||||||
Methodology: |
Chemiluminescence |
||||||||
Synonyms: |
EB-IgM, EBV IGM, EBVCAM Epstein Barr IgM Antibody Epstein Barr Virus IgM Antibodies to Viral Capsid
|
||||||||
Clinical significance: |
Epstein-Barr virus (EBV) is responsible for infectious mononucleosis (IM) and has also been implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV-VCA IgM antibodies typically appear within 4-6 weeks of infection with IM, peak concurrently with clinical onset of the disease, and decline within 2-3 months. A positive EBV-VCA IgM antibody in conjunction with clinical findings is indicative of an active or recent infection. | ||||||||
Doctoral Director(s:) |
Hoi-Ying Elsie Yu PhD, DABCC | ||||||||
Review Date: | 12/13/2022 |